{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:21:30Z","timestamp":1789737690417,"version":"4.0.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.eururo.2013.03.055","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T09:20:08Z","timestamp":1365067208000},"page":"232-239","source":"Crossref","is-referenced-by-count":63,"title":["Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group"],"prefix":"10.1016","volume":"66","author":[{"given":"Fernando Calais da","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Manuel Calais da","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederico","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9rico","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kliment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicos","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spiro","family":"Pastidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Marques Queimadelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.03.055_bib0005","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on prostate cancer. European Association of Urology Web site. http:\/\/www.uroweb.org\/gls\/pdf\/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf."},{"key":"10.1016\/j.eururo.2013.03.055_bib0010","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.eururo.2009.02.016","article-title":"Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group","volume":"55","author":"Calais da Silva","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.18_suppl.4","article-title":"Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial [abstract 4]","volume":"30","author":"Hussain","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0020","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.5015","article-title":"Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5015]","volume":"25","author":"Miller","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(18)38683-X","article-title":"Intermittent is as effective as continuous androgen deprivation in patients with PSA-relapse after radical prostatectomy (RP) [abstract 1458]","volume":"171","author":"Tunn","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2009.07.049","article-title":"Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature","volume":"57","author":"Abrahamsson","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0035","first-page":"2275","article-title":"Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma","volume":"50","author":"Bruchovsky","year":"1990","journal-title":"Cancer Res"},{"issue":"Suppl","key":"10.1016\/j.eururo.2013.03.055_bib0040","article-title":"A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/UK Intercontinental Trial CRUKE\/01\/013) [abstract 4514]","volume":"29","author":"Crook","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0045","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statistics"},{"key":"10.1016\/j.eururo.2013.03.055_bib0050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.eururo.2013.03.055_bib0055","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/ncponc1180","article-title":"Intermittent androgen blockade should be regarded as standard therapy in prostate cancer","volume":"5","author":"Seruga","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0060","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1464-410X.2007.06770.x","article-title":"International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients","volume":"99","author":"Shaw","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.055_bib0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1464-410X.2003.04015.x","article-title":"Intermittent androgen suppression in patients with prostate cancer","volume":"91","author":"De la Taille","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.055_bib0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.eururo.2008.02.024","article-title":"Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study","volume":"54","author":"Irani","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0085","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.urolonc.2011.03.008","article-title":"Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer","volume":"31","author":"Langenhuijsen","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2013.03.055_bib0080","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc B"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813003424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T05:58:10Z","timestamp":1715147890000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813003424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0302283813003424"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.03.055","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006688.793476966","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]}}}